Brisbane Economic Development Agency’s Post

The post-COVID-19 #medtech industry continues to be a difficult space for both investors and entrepreneurs, but support for #innovation is still available for companies that can navigate the challenges of early commercialization and reimbursement, according to the presenters at the Transcatheter Cardiovascular Therapeutics conference in Washington, DC. #TCT2024 Featuring: • Andrew Cleeland - Moderator, Fogarty Innovation • Amr Salahieh - Moderator, President and CEO of Shifamed • Jan Garfinkle - Founder and Managing Partner of Arboretum Ventures. • Todd Brinton, MD - Chief Scientific Officer, Edwards Lifesciences • Sean Salmon - President of Medtronic’s Cardiovascular Businesses • Josh Makower, MD - Professor of Medicine and Bioengineering, Stanford University; Director of the Byers Center for Biodesign (Stanford Mussallem Center for Biodesign) The 2024 MedTech Innovation Forum at the Transcatheter Cardiovascular Therapeutics conference in Washington, DC, featured a lively discussion among industry veterans on the biggest challenges facing #medtech innovators in the coming years: https://bit.ly/3ALczuI

Latin America's Diagnostic Breakthroughs In the current landscape of diagnostic technologies, medium throughput solutions are emerging as a significant commercial opportunity, especially in Latin America, where innovative companies are making remarkable progress. Geneprodx from Chile recently launched its diagnostic platform for thyroid nodules using Idylla technology, showcasing how medium throughput solutions can provide accurate and rapid diagnoses at a reasonable cost. TIMSER GROUP from Mexico has gained approval for its Preventix kit, aimed at early detection of cervical cancer, highlighting the effectiveness of these technologies in addressing critical medical needs. ZEV Biotech, operating in Argentina and Brazil, offers an even more integrated example with its IRIS platform, focused on antimicrobial resistance (AMR). Their fully integrated approach and commitment to medium throughput solutions allow them to address specific market niches and offer more accessible diagnostics in terms of cost and technological complexity. These ventures illustrate that the medium throughput segment is not only viable but crucial, filling a gap between low and high throughput technologies that often do not suit the realities of diagnostics in emerging markets. This segment allows for simpler implementation compared to high throughput technologies, which require significant investments in equipment and specialized training, and are more versatile than low throughput technologies, which, although simpler, are often inadequate for addressing more complex pathologies. The situation in Latin America reflects a window of opportunity for medium throughput technologies, especially as large international corporations often focus on more developed markets. This landscape provides fertile ground for local innovators like Geneprodx, TIMSER GROUP, and ZEV Biotech to advance, overcoming obstacles and setting new standards in healthcare in the region. The story of these ventures is a source of inspiration and a reminder that, although biotechnology and molecular diagnostics may be dominated by first-world powers, there are significant opportunities in substantial markets like Latin America. As Steve Jobs once said, "Innovation distinguishes between a leader and a follower." These emerging leaders are not just innovating; they are paving the way toward a healthier future in their communities. #DiagnosticInnovation #LatAmDx #MidThroughput #BiotechLatAm #ZentynelVC

Meeting a unique team was such an honour! ARTHEx Biotech is an EIC Accelerator beneficiary, based in Spain. I met this dynamic and hard working team at their premises in Valencia, where the heart of the company is beating, modulating microRNAs and developing innovative medicines, tailored to patients’ specific needs. EIC Accelerator blended finance is awarded for the development of a brand new treatment to Myotic Dystrophy Type 1 (DM1), an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000). This condition has currently no cure, and no approved treatment. A first-in-class disease modifying therapy, ATX-01, developed by ARTHEx, addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis. ARTHEx biotech is a spin-off biotech company from the University of Valencia. They have grown from 1 person in 2019 when the company was founded to a team of 20 right now. The EIC Accelerator grant is used to support Phase I/IIa clinical trial of ATX-01 for DM1. beatriz llamusi PhD, CSO & Co-Founder of ARTHEx biotech mentioned: “This grant empowers us to bridge the gap between foundational scientific research and clinical application, driving the development of ATX-01 for DM1. With its dual mechanism, we're confident in our potential to set a new standard in treatment within the DM1 space.”   It is simply amazing to see European players raising up to their potential to bring best-in-class treatments in the global fight against rare diseases. To learn more about their approach and pipeline visit ARTHEx Biotech https://lnkd.in/ddBQyg-E #EUeic, #eicAccelerator #MyotonicDystrophy #biotech #financing #microRNA  

Prenetics Global Limited (NASDAQ: PRE), a genomics-driven health sciences company, is making waves in the industry. With its three primary units – CircleDNA, Insighta, and ACT Genomics – PRE is advancing personalized medicine, early cancer detection, and genomic profiling for personalized cancer treatments. In the first quarter of 2024, PRE reported impressive financial results, including a 30.2% increase in revenue and a 159.8% surge in gross profit compared to the previous year. The company's strategic focus on the US consumer healthcare market aims to broaden accessibility to its science-based solutions. 'The first quarter of 2024 marked a good start for our company, showcasing solid growth in revenue and gross profit. These results demonstrate firm governance of our financial position with no debt, supported by a resilient and talented team,' said Danny Yeung, Chief Executive Officer and Co-Founder of PRE. PRE recently announced a partnership with former international footballer David Beckham, who has become a strategic investor and co-founding partner of a new health and wellness brand, IM8. 'This partnership with David marks a transformative era for PRE in global health innovation and wellness,' Yeung stated. With its innovative approach, strong financial performance, and high-profile collaborations, Prenetics Global Limited is poised to drive significant advancements in genomics and consumer health. #genomics #personalizedmedicine #cancerdetection #healthinnovation

From pipeline developments and clinical milestones to new partnerships, hear from the CEOs and leaders of #FlagshipFounded companies advancing novel science and platforms to make #BiggerLeaps for human health. Watch all the conversations: https://lnkd.in/eXA6nUcD     🔹 Lovisa Afzelius, Co-founder & CEO, Prologue Medicines  🔹 Brian Alexander, CEO, Valo Health 🔹 Stéphane Bancel, CEO, Moderna  🔹 Jason Gardner, CEO, Ampersand Biomedicines  🔹 Margo Georgiadis, Co-founder & CEO, Montai Therapeutics   🔹 Adrian Gottschalk, CEO, Foghorn Therapeutics Inc.  🔹 Steve Hahn, CEO, Harbinger Health  🔹 Steve Harr, CEO, Sana Biotechnology, Inc.   🔹 Angela Hwang, CEO, Metaphore Biotechnologies  🔹 John Lepore, MD, CEO, ProFound Therapeutics   🔹 Michael Nally, CEO, Generate:Biomedicines  🔹 Jason Park, Co-founder & CEO, Empress Therapeutics   🔹 Guillaume Pfefer, CEO, Sail Biomedicines   🔹 Jacob Rubens, CEO, Quotient Therapeutics   🔹 Michael Severino, CEO, Tessera Therapeutics  🔹 Eric Shaff, CEO, Seres Therapeutics 🔹 Torben Straight Nissen, CEO, Repertoire Immune Medicines  🔹 Jens H. Vogel, Ph.D., President & COO, Mirai Bio   🔹 Michelle Werner, CEO, Alltrna   🔹 Craig Williams, CEO, Apriori Bio    #JPM25 #FlagshipStudio 

🌐 Key Insights from Outcome Capital's November 2024 Life Sciences Market Pulse. Outcome Capital’s latest report provides a deep dive into the trends shaping #MedTech, #biotech, #diagnostics, and #healthcare. With expert analyses and key transaction updates, this edition is a must-read for industry professionals.   📌 Highlights: ✅ Aya Healthcare Acquires Cross Country Healthcare: $615M deal focusing on operational efficiency and tech-driven workforce management. ✅ ZAP Surgical Systems, Inc.’s $78M Series E Financing: A breakthrough for minimally invasive neurosurgery with the ZAP-X® platform. ✅ Roche’s $1.5B Acquisition of Poseida Therapeutics, Inc.: Strengthening CAR-T cell therapy innovations. ✅ Diagnostics Sector Challenges: CENTOGENE transitions to private ownership amid market hurdles.   🚀 Don’t just read about the future—experience it firsthand!   👉Read more about the report here: https://lnkd.in/gC5Wkwnh   📰Want to stay updated on industry news and market trends? Subscribe to our Newsletter: https://lnkd.in/gWPYEdAN   📅Join the conversation at MedTech Malta 2025, happening from November 12 to 14 in Valletta, Malta. #MedTech #MedTechWorld #healthcare #medtechmalta2025 #MedTechMalta #healthtech  

What does it take to lead a first-in-class biotech company? From pipeline breakthroughs to transformative partnerships, the CEOs and leaders of #FlagshipFounded companies are pushing the frontiers of science to make #BiggerLeaps for human health and sustainability. 🔬 Hear their insights. See their impact. Watch the conversations. Come join us 👀 #WeAreFlagship #FlagshipPioneering

🗓️ Mark your calendars for Tuesday, October 29, at 12:00 PM ET during #BioFuture2024 for the panel discussion, "Tech Innovations of the Future: Deep Tech and AI will Impact Every Aspect of Healthcare."    Moderated by Beth Rogozinski, CEO of Oncoustics, this session will explore how #AI and #Deeptech are set to revolutionize nearly every area of healthcare—from predicting pandemics to enabling point-of-care diagnostics, remote patient monitoring, and enhancing drug discovery. The panel will focus on the current and emerging technologies reshaping #healthcare and their expected impacts on incumbents and the entire healthcare ecosystem. Panelists include:  🔹 Vinona Bhatia MD MPH, Founder, P4CI Partnering for Cancer Innovation  🔹 Remo Moomiaie-Qajar M.D., President & CEO, Cytonus Therapeutics.  🔹 Georgia Ravitz, Partner, FDA & Healthcare Regulatory, Orrick, Herrington & Sutcliffe LLP   🔗 Reserve your seat now: https://lnkd.in/gm7cvWsE   🗓️ View the full agenda here: https://lnkd.in/gQV2zSbF Join hundreds of global thought leaders at BioFuture™ 2024 from October 28-30 at Cure. in #NYC. Connect with venture capitalists, strategic investors, and key players in pharma and biotech to discover what’s next in healthcare innovation. 👉 Learn more about BioFuture here: https://lnkd.in/gVVHpGfe  #BioFuture #Biotech #HealthcareInnovation #AI #DrugDiscovery #TechBio #HealthcareInnovation #Therapeutics #DigitalHealth #DemyColton 

🔬 Actio Biosciences Launches with $55M Series A, Partners with Jackson Laboratory TL;DR: • $55M funding led by Canaan and Droia Ventures • Strategic partnership with Jackson Laboratory for mouse models • Initial focus on Charcot-Marie-Tooth disease • Targeting TRPV4 ion channel protein Exciting developments in the rare disease space! San Diego-based Actio Biosciences is making waves with a dual announcement that's turning heads in biotech. The startup is pioneering a unique approach to drug development, leveraging Mendelian disease research to bridge rare and common disease treatments. Their collaboration with Jackson Laboratory will create advanced mouse models that better mimic human diseases. CEO David Goldstein's strategy? Understanding disease mechanisms first, then developing targeted therapies that could impact both rare and common conditions. Starting with Charcot-Marie-Tooth Type 2C, they're exploring TRPV4's role in both neurodegenerative and bone disorders. Notable industry veterans George Golumbeski and John McHutchinson join as advisors, bringing decades of expertise to guide this promising venture. 💭 What are your thoughts on this approach to rare disease drug development? Could this model revolutionize how we bridge rare and common disease treatments? #Biotech #RareDiseases #DrugDevelopment #Innovation #BiotechNews #intelligencesimplified #pharma #biotech #biodatastudio

🏆 2024 FACCNE'S FAB AWARDS FINALISTS UNVEILED! 🏆 🧠 Innovation Award - Imaginostics: creating the next generation of precision medicine diagnostic tools to serve clinicians and drug developers to transform personalized healthcare, accelerate drug development, and fight aging. - ReST THERAPEUTICS: develops breakthrough therapies to treat complex neurological and psychiatric disorders, by revisiting NMDA targeted selective inhibition - REEV (techstars '23): revolutionizing personal mobility for millions who struggle with walking disorders through innovative, AI-powered wearable exoskeletons. 🌍 Sustainability Award - Spare-it: Pioneering how organizations measure and reduce their in-building waste - Sesame Sustainability: Understand, de-risk, and execute the decarbonization journey with confidence, through modeling, optimization, and analysis. 🧬 Life Sciences Award - Small companies - Owkin: Using AI to find the right treatment for every patient - Amolyt Pharma: Delivering life-changing treatments to patients suffering from rare endocrine and related diseases. 🧪 Life Sciences Award - Large companies - CELLforCURE by Seqens: Trustworthy development and commercial manufacturing of CELL&GENE therapies - TreeFrog Therapeutics: Cell therapy for all: where innovation meets hope in the realm of cell therapy. Get your tickets for the pitch competition at: https://lnkd.in/d5UJUPms This event is made possible thanks to our sponsors: Gold Sponsors: Banque Transatlantique, Ipsen, EY, ORCOM US, Veolia North America, Silver Sponsor: Keolis North America Inc. Bronze Sponsors: Fragomen, Fitch Law Partners LLP #boston #newengland #awards #lifesciences #innovation #sustainability #entrepreneurship